Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL28903894 | 0.97 | TSHR (0.67) | TSHRTP53TDP1PPARDCYP3A4 | |
| SCHEMBL388425 | 0.94 | — | — | |
| Triethyl Phosphate SCHEMBL3850859 | 0.91 | TSHR (0.77) | TSHRTP53TDP1PPARDCYP3A4 | |
| Ammonia Solution, Strong SCHEMBL9049883 | 0.91 | TSHR (0.67) | TSHRTP53TDP1PPARDCYP3A4 | |
| SCHEMBL20261798 | 0.91 | TSHR (0.67) | TSHRTP53TDP1PPARDCYP3A4 | |
| SCHEMBL20261836 | 0.91 | TSHR (0.67) | TSHRTP53TDP1PPARDCYP3A4 | |
| SCHEMBL3821844 | 0.88 | TSHR (0.63) | TSHRTP53TDP1PPARDCYP3A4 | |
| SCHEMBL17359429 | 0.87 | TSHR (0.55) | TSHRTP53TDP1PPARDCYP3A4 | |
| SCHEMBL575527 | 0.87 | TSHR (0.55) | TSHRTP53TDP1PPARDCYP3A4 | |
| SCHEMBL28146249 | 0.87 | TSHR (0.55) | TSHRTP53TDP1PPARDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378117-B2 | Dispersion and coating composition containing lithium metal phosphate | EVONIK OPERATIONS GMBH (DE) | 2025-08-05 | — | — | US | claimed |
| US-12240798-B2 | Electrolyte, and electrochemical device and electronic device including same | NINGDE AMPEREX TECHNOLOGY LIMITED (CN) | 2025-03-04 | — | — | US | claimed |
| US-12046756-B2 | Cellulose derivative composition for secondary battery binder and method of preparing composition for secondary battery electrode comprising the same | ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE (KR) | 2024-07-23 | — | — | US | claimed |
| CN-117747922-A | Flame-retardant composite electrolyte, manufacturing method and flame-retardant lithium battery | 新加坡国立大学 | 2024-03-22 | — | — | CN | claimed |
| WO-2024056011-A1 | FLAME-RETARDANT COMPOSITE ELECTROLYTE, MANUFACTURING METHOD, AND FLAME-RETARDANT LITHIUM BATTERY | 新加坡国立大学 | 2024-03-21 | — | — | WO | claimed |
| EP-4060780-B1 | DISPERSION AND COATING COMPOSITION CONTAINING LITHIUM METAL PHOSPHATE | EVONIK OPERATIONS GMBH (DE) | 2023-07-26 | — | — | EP | claimed |
| CN-113122937-B | Preparation method of flexible high-strength inorganic nano-reticular pulse structure luminescent film | 西安工程大学 | 2023-01-24 | — | — | CN | claimed |
| CN-113123018-B | Preparation method of metal oxide nanofiber membrane with flexible reticular vein structure | 西安工程大学 | 2023-01-24 | — | — | CN | claimed |
| CN-113117434-B | Preparation method of flexible reticular vein structure ceramic nanofiber ultrahigh-temperature filtering membrane | 西安工程大学 | 2022-11-22 | — | — | CN | claimed |
| CN-113416591-B | Preparation method of mixed phosphate lubricant | 上海应用技术大学 | 2022-10-14 | — | — | CN | claimed |
| CN-104662687-A | Salts of phosphorus oxide for use as n-type dopants in organic electronic devices | SIEMENS AG | 2015-05-27 | — | — | CN | claimed |
| CN-104250280-A | Antioxidant inflammation regulator C-17 homologized oleanolic acid derivatives | REATA PHARMACEUTICALS INC | 2014-12-31 | — | — | CN | claimed |
| CN-102066398-B | Antioxidant inflammation regulator C-17 homologized oleanolic acid derivatives | REATA PHARMACEUTICALS INC | 2014-09-10 | — | — | CN | claimed |
| CN-102066398-A | Antioxidant inflammation regulator C-17 homologized oleanolic acid derivatives | REATA PHARMACEUTICALS INC | 2011-05-18 | — | — | CN | claimed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | claimed |
| US-5245004-A | ANHYDROUS POLYMERIZATION OF CAPROLACTAM WITH CATALYST, COCATALYST AND ACTIVATOR | UNITIKA LTD. (JP) | 1993-09-14 | — | — | US | claimed |
| EP-0522533-A1 | Process for polymerizing epsilon-caprolactam | UNITIKA LTD. (JP) | 1993-01-13 | — | — | EP | claimed |
| EP-0251952-B1 | PROCESS FOR THE PREPARATION OF POLYISOCYANATES HAVING A BIURET STRUCTURE | RHONE-POULENC CHIMIE (FR) | 1992-09-30 | — | — | EP | claimed |
| US-4983762-A | From aliphatic, alicyclic or arylaliphatic diisocyanate, water, liquid form, carbon dioxide | RHONE-POULENC CHIMIE DE BASE (FR) | 1991-01-08 | — | — | US | claimed |
| US-3953539-A | PHOSPHORUS COMPOUNDS | TEIJIN LTD. (JA) | 1976-04-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240798-B2 | Electrolyte, and electrochemical device and electronic device including same | KCNQ1, HCN2, KCNQ4 | TSHR 3953/4885TP53 3493/4885TDP1 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.